Eneboparatide

Peptide

Also known as AZP-3601

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Phase 3underway

Evidence outlook · registrational

Hypoparathyroidism: registrational readout pending

Its supporting mid-stage studies have completed. The registry records primary completion on 2024-11-15; results are not yet reported. Check News for topline announcements.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Hypoparathyroidism
NCT05778071 · Alexion Pharmaceuticals, Inc.
2023-06-07 – 2027-06-16 · Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
What this study did
Phase 1/2 (1)
Hypoparathyroidism
NCT05239221 · Alexion Pharmaceuticals, Inc.
2020-09-07 – 2022-08-23 · Chronic Hypoparathyroidism
What this study did

Competitive landscape

This drug's own stage for Hypoparathyroidism: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Eneboparatide: this drugPhase 3PeptideParathyroid hormone receptor 1 (PTH1R)not yet gradedNo reviewed efficacy summary in this indication
Palopegteriparatide (Yorvipath)ApprovedPeptidePTH1 receptor (PTH replacement)Reliable signal
NCT04701203: Efficacy - Primary Endpoint During the Blinded Period (26 weeks): TransCon PTH 78.7 Percentage of participants (95% CI 66.3 to 88.1) | Placebo 4.8 Percentage of participants (95% CI 0.1 to 23.8)

Upcoming events

No upcoming readouts on record for this asset.